SAN FRANCISCO, Oct. 3, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, will present new healthcare and cost outcomes data for its MF59®-adjuvanted trivalent influenza vaccine (FLUAD) at
Growth Capitalist (https://growthcapitalist.com/2018/10/seqirus-presents-favorable-outcomes-data-for-adjuvanted-trivalent-influenza-vaccine-fluad-at-6th-annual-idweek/)
SAN FRANCISCO, Oct. 3, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, will present new healthcare and cost outcomes data for its MF59®-adjuvanted trivalent influenza vaccine (FLUAD) at